Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis

Table 2 Comparison of laboratory indicators and JADAS-10 scores between the two groups (n, %)

Indicator	Time	Etanercept Group (n = 33)	Adalimumab Group (n = 33)	t	P	Significant difference in normal distribution (P)
CCP (RU/mL)	1 day before treatment	26.76 ± 2.32	26.47 ± 2.17	-0.716	0.475	0.553
	1 month after treatment	9.87 ± 1.03	6.93 ± 1.08	-16.004	<0.001	0.260
	3 months after treatment	4.39 ± 0.41	3.42 ± 0.37	-16.004	<0.001	0.096
TNF-α (ng/mL)	1 day before treatment	8.76 ± 1.37	8.68 ± 1.42	-0.329	0.742	0.343
	1 month after treatment	5.19 ± 0.76	4.03 ± 0.81	-8.484	<0.001	0.193
	3 months after treatment	4.18 ± 0.72	3.76 ± 0.69	-3.422	0.001	0.174
CRP (ng/mL)	1 day before treatment	12.39 ± 1.32	12.45 ± 1.24	0.269	0.788	0.315
	1 month after treatment	5.03 ± 1.06	4.09 ± 1.08	-5.046	<0.001	0.263
	3 months after treatment	4.14 ± 1.09	3.53 ± 1.14	-3.142	0.021	0.275
ESR (mm/H)	1 day before treatment	22.18 ± 2.13	22.36 ± 2.09	0.490	0.625	0.519
	1 month after treatment	15.56 ± 1.09	13.74 ± 1.05	-9.769	<0.001	0.263
	3 months after treatment	13.87 ± 1.14	13.08 ± 1.32	-3.680	<0.001	0.304
White blood cell count (10 × 10⁹/L)	1 day before treatment	10.63 ± 1.45	10.56 ± 1.54	-0.269	0.789	0.368
	1 month after treatment	5.76 ± 0.74	4.31 ± 1.55	-6.858	<0.001	0.301
	3 months after treatment	3.87 ± 0.67	3.45 ± 0.63	-3.710	<0.001	0.160
JADAS-10 (score)	1 day before treatment	23.87 ± 0.45	23.82 ± 0.53	-0.584	0.560	0.121
	1 month after treatment	8.34 ± 0.42	6.39 ± 0.39	-27.640	<0.001	0.100
	3 months after treatment	7.42 ± 0.17	5.89 ± 0.13	-58.081	<0.001	0.076

Note: CCP, Cyclic Citrullinated Peptide; TNF-α, Tumor Necrosis Factor-alpha; CRP, C-Reactive Protein; ESR, Erythrocyte Sedimentation Rate; JADAS-10, Juvenile Arthritis Disease Activity Score in 10 joints

ISSN: 1471-2431